Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Suven Life Sciences Limited
Press Release Aug 16 2021
Aug 16 2021
4 min read

Press Release Aug 16 2021

Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 16, 2021, titled "Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonist for treatment of Agitation and aggression in Alzheimer s type dementias".

View Attachment